Scinovex
review Open AccessTop 1% cited

Chronic thromboembolic pulmonary hypertension

European Respiratory Journal · 2018 · Vol. 53(1) · pp. 1801915–1801915
Nick H. KimMarion DelcroixXavier JaïsMichael M. MadaniHiromi MatsubaraEckhard MayerTakeshi OgoVictor F. TapsonHossein Ardeschir GhofraniDavid P. Jenkins

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of pulmonary embolism and a major cause of chronic PH leading to right heart failure and death. Lung ventilation/perfusion scintigraphy is the screening test of choice; a normal scan rules out CTEPH. In the case of an abnormal perfusion scan, a high-quality pulmonary angiogram is necessary to confirm and define the pulmonary vascular involvement and prior to making a treatment decision. PH is confirmed with right heart catheterisation, which is also necessary for treatment determination. In addition to chronic anticoagulation therapy, each patient with CTEPH should receive treatment assessment starting with evaluation for pulmonary endarterectomy, which is the guideline recommended treatment. For technically inoperable cases, PH-targeted medical therapy is recommended (currently riociguat based on the CHEST studies), and balloon pulmonary angioplasty should be considered at a centre experienced with this challenging but potentially effective and complementary intervention.

Pulmonary Hypertension Research and TreatmentsVenous Thromboembolism Diagnosis and ManagementCardiovascular Function and Risk FactorsMedicineRiociguatPulmonary embolismPulmonary hypertensionAngioplastyScintigraphyEndarterectomyChronic thromboembolic pulmonary hypertensionGuidelineComplication
Citations
978
FWCI
54.25
field-weighted impact
References
112
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.